MD

Pediatrix Medical Group, Inc. - 10-Q Summary (Period Ended Sep 30, 2004)

Business Context and Reporting Period

This is a Quarterly Report on Form 10-Q for Pediatrix Medical Group, Inc. (PMG), covering the three and nine months ended September 30, 2004. PMG operates as a national provider of pediatric medical services through affiliated professional contractors. The company completed eight physician group practice acquisitions during the nine-month period, with a total consideration of approximately $41.7 million.

Key Financial Metrics

Note: Debt figures represent total debt (current + long-term) as of September 30, 2004. The company had no outstanding principal balances under its $150 million line of credit at period end.

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 8.8% ($12.8 million) for the quarter and 13.1% ($53.2 million) for the nine months compared to 2003. Approximately 76% of the quarterly increase and 54% of the nine-month increase were attributable to acquisitions and new hospital contracts.
• Same-Unit Growth: Same-unit revenue grew 2.2% for the quarter and 6.3% for the nine months, driven by increased neonatal intensive care patient days and volume growth in maternal-fetal services.
• Profitability: Net income rose 10.5% for the quarter and 20.1% for the nine months. Operating margins decreased slightly for the quarter (26.2% vs 26.3%) due to a shift in payor mix toward government programs (Medicaid) which reimburse at lower rates than commercial insurance. However, the nine-month operating margin improved to 25.3% from 24.2%.
• Expenses: Practice salaries and benefits increased 10.5% (quarter) and 12.4% (nine months) due to acquisition-related staffing and volume growth. General and administrative expenses remained relatively flat for the quarter but increased 4.0% for the nine months.

Guidance, Outlook, Risks, and Unusual Items

• Capital Allocation: The company is aggressively repurchasing stock. During the nine months ended September 30, 2004, it repurchased 851,000 shares for $57.3 million. In October 2004 (subsequent event), it completed an additional $92.7 million in repurchases.
• Liquidity: In July 2004, the company secured a new $150 million revolving line of credit maturing in 2009. While no principal was outstanding at September 30, 2004, the company borrowed $60.0 million under this facility in October 2004 to finance stock repurchases and an acquisition.
• Legal and Regulatory Risks: The company faces ongoing investigations by the Federal Trade Commission (FTC) regarding competition issues related to a 2001 acquisition. Additionally, there are active federal and state investigations into Medicaid and TRICARE billing practices, including a search warrant served in Nevada in November 2003. Management cannot predict the outcome or potential financial impact of these inquiries.
• Insurance: The company noted that professional liability insurance costs have increased and coverage must be renewed annually, posing a risk if terms become unfavorable or coverage is insufficient for future claims.

Investor Verification Checklist

• Payor Mix Impact: Verify the extent to which the shift toward government payors (Medicaid) will continue to compress operating margins in future quarters.
• Regulatory Exposure: Monitor the status of the FTC investigation and the federal/state Medicaid billing inquiries for potential fines, restitution, or operational restrictions.
• Debt Utilization: Confirm the utilization of the new $150 million credit facility, noting the $60 million drawdown reported in October 2004, and assess the impact on future interest expenses.
• Acquisition Integration: Evaluate the financial performance of the eight practices acquired in 2004 to ensure they meet projected revenue and margin targets.
• Stock Repurchase Sustainability: Assess whether the aggressive share buyback program ($150 million+ in 2004) is sustainable given the company's cash flow and debt covenants.